Targeted Therapies | Navigating the Business Challenges of Personalized Medicine | Center for Health Solutions

Simultaneously buoyed by advances in science and technology and fueled by a rapid decrease in the unit cost of genome sequencing and related tools, the concept of personalized medicine, or targeted therapies, is becoming reality. The potential benefits to society are substantial: the promise of understanding the molecular basis of wellness and disease; the development of highly targeted, individualized diagnostics and therapeutic regimens; and the creation of treatments leading to delayed progression or the cessation of disease and, at some point, elimination of disease before it even is manifested. As exciting as these advancements may be, however, the health care industry is discovering there is a difference between what is possible and what is practical and payable, as the science of targeted therapies is rapidly outpacing the economics.

The emergence and adoption of targeted therapies will generate opportunities and challenges for stakeholders across the entire life sciences and health care value chain: consumers, life sciences companies, payors, providers and government agencies/regulators. Aligning incentives among these stakeholders is essential to help drive the convergence of science, policy and economics that is needed to create a road map to success. However, such alignment will require a level of intra- and cross-industry collaboration that currently does not exist.

The Deloitte Center for Health Solutions, a part of Deloitte LLP, has released a new point of view, “Targeted Therapies: Navigating the Business Challenges of Personalized Medicine.” This paper examines the rapidly evolving field of personalized medicine from the perspective of those stakeholders who are responsible for driving or limiting its adoption, implementation and use over the next several years and decades. It also discusses the need for significant collaboration among these stakeholders as a prerequisite for overcoming challenges and realizing the full promise of targeted therapies.

To access the report, download the attached document below.